These findings have important clinical relevance since one limitation of general Rho inhibitors for the treatment of cardiovascular disease is the undesirable secondary effects; for Y-27632, these include the reduction of systemic and pulmonary arterial pressures under resting baseline conditions, due to its broad effects on cytoskeletal dynamics. Here, RHO is linked to cardiovascular disorder.